EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance

Aniruddha S Karve iD, Janki M Desai iD, Sidharth N Gadgil, Nimita Dave, Trisha M Wise-Draper, Gary A Gudelsky, Timothy N Phoenix, Biplab DasGupta, Lalanthica Yogendran, Soma Sengupta iD, David R Plas iD, Pankaj B Desai

International Journal of Molecular Sciences · 12.03.2024 · 25 (6) · 3217

DOI: 10.3390/ijms25063217 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 12.03.2024. Verfasst von Aniruddha S Karve und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA. Hauptthemen laut MEDLINE: Glioblastoma, Brain Neoplasms. Die Arbeit wurde bisher 54-mal zitiert (Crossref) und nennt 90 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NINDS NIH HHS, University of Cincinnati Brain Tumor Center.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A glioblastoma (GBM) is one of the most aggressive, infiltrative, and treatment-resistant malignancies of the central nervous system (CNS). The current standard of care for GBMs include maximally safe tumor resection, followed by concurrent adjuvant radiation treatment and chemotherapy with the DNA alkylating agent temozolomide (TMZ), which was approved by the FDA in 2005 based on a marginal increase (~2 months) in overall survival (OS) levels. This treatment approach, while initially successful in containing and treating GBM, almost invariably fails to prevent tumor recurrence. In addition to the limited therapeutic benefit, TMZ also causes debilitating adverse events (AEs) that significantly impact the quality of life of GBM patients. Some of the most common AEs include hematologic (e.g., thrombocytopenia, neutropenia, anemia) and non-hematologic (e.g., nausea, vomiting, constipation, dizziness) toxicities. Recurrent GBMs are often resistant to TMZ and other DNA-damaging agents. Thus, there is an urgent need to devise strategies to potentiate TMZ activity, to overcome drug resistance, and to reduce dose-dependent AEs. Here, we analyze major mechanisms of the TMZ resistance-mediated intracellular signaling activation of DNA repair pathways and the overexpression of drug transporters. We review some of the approaches investigated to counteract these mechanisms of resistance to TMZ, including the use of chemosensitizers and drug delivery strategies to enhance tumoral drug exposure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlioblastomaBrain NeoplasmsHumansTemozolomideAntineoplastic Agents, AlkylatingQuality of LifeNeoplasm Recurrence, LocalDNADrug Resistance, NeoplasmCell Line, Tumor

Stichwörter der Autor:innen

combination therapeuticsglioblastomatreatment resistance

Substanzen

TemozolomideAntineoplastic Agents, AlkylatingDNA

Autor:innen und Institutionen

  • Division of Pharmaceutical Sciences, James L. Winkle College of Pharmacy, University of Cincinnati, Cincinnati, OH 45267, USA.
  • Lapix Therapeutics, Cambridge, MA 02142, USA.
  • Division of Hematology/Oncology, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
  • Division of Oncology, Cincinnati Children's Hospital, Cincinnati, OH 45229, USA.
  • Department of Neurology & Rehabilitation Medicine, University of Cincinnati College of Medicine, Cincinnati, OH 45267, USA.
  • Department of Neurology, School of Medicine, University of North Carolina, Chapel Hill, NC 27514, USA.

ORCID-Profile: Aniruddha S Karve, Janki M Desai, Soma Sengupta, David R Plas

Förderung

  • NCI NIH HHS
  • NINDS NIH HHS
  • University of Cincinnati Brain Tumor Center
  • National Institute of Neurological Disorders and Stroke (NINDS/NIH)

Zitieren

APA

Karve, A. S., Desai, J. M., Gadgil, S. N., Dave, N., Wise-Draper, T. M., Gudelsky, G. A., Phoenix, T. N., DasGupta, B., Yogendran, L., Sengupta, S., Plas, D. R., & Desai, P. B. (2024). A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance. International Journal of Molecular Sciences, 25(6), 3217. https://doi.org/10.3390/ijms25063217

Vancouver

Karve AS, Desai JM, Gadgil SN, Dave N, Wise-Draper TM, Gudelsky GA, et al. A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance. International Journal of Molecular Sciences. 2024;25(6):3217. doi:10.3390/ijms25063217

BibTeX
@article{Karve2024,
  author = {Karve, Aniruddha S and Desai, Janki M and Gadgil, Sidharth N and Dave, Nimita and Wise-Draper, Trisha M and Gudelsky, Gary A and Phoenix, Timothy N and DasGupta, Biplab and Yogendran, Lalanthica and Sengupta, Soma and Plas, David R and Desai, Pankaj B},
  title = {A Review of Approaches to Potentiate the Activity of Temozolomide against Glioblastoma to Overcome Resistance},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  volume = {25},
  number = {6},
  pages = {3217},
  doi = {10.3390/ijms25063217}
}
Kostenlos starten →